{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:29:32Z","timestamp":1740126572615,"version":"3.37.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,31]]},"DOI":"10.1093\/eurheartj\/ehab154","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T11:22:46Z","timestamp":1617276166000},"page":"1185-1189","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-8846","authenticated-orcid":false,"given":"Filippo","family":"Crea","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy"},{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"2021070720500789700_ehab154-B1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurheartj\/ehz916","article-title":"The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context","volume":"42","author":"McMurray","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","article-title":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Packer","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B3","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/eurheartj\/ehaa731","article-title":"Totality of evidence in trials of sodium\u2013glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice","volume":"41","author":"Butler","year":"2020","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/eurheartj\/ehab057","article-title":"Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care","volume":"42","author":"Spertus","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/eurheartj\/ehx209","article-title":"Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints","volume":"40","author":"Rossignol","year":"2019","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021070720500789700_ehab154-B9","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab094","article-title":"for the DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehab092","article-title":"Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial","volume":"42","author":"Marx","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/eurheartj\/ehu493","article-title":"The research venture in arrhythmogenic right ventricular cardiomyopathy: a paradigm of translational medicine","volume":"36","author":"Thiene","year":"2015","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B12","first-page":"3227","article-title":"Treatment of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: an international task force consensus statement","volume":"36","author":"Corrado","year":"2015","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/eurheartj\/ehz669","article-title":"Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis","volume":"41","author":"Corrado","year":"2020","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehaa821","article-title":"Arrhythmias right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry","volume":"42","author":"Gasperetti","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/eurheartj\/ehy422","article-title":"Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis","volume":"40","author":"O\u2019Shaughnessy","year":"2019","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/eurheartj\/ehy544","article-title":"Cardiovascular outcomes in dialysis patients: one size does not fit all","volume":"40","author":"Bowman","year":"2019","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/eurheartj\/ehaa1049","article-title":"The cardiovascular\u2013dialysis nexus: the transition to dialysis is a treacherous time for the heart","volume":"42","author":"Chan","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/eurheartj\/ehx402","article-title":"Refining the prognostic impact of functional mitral regurgitation in chronic heart failure","volume":"39","author":"Goliasch","year":"2018","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B20","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/ehab086","article-title":"The management of secondary mitral regurgitation in patients with heart failure. A joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/eurheartj\/ehab070","article-title":"Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside","volume":"42","author":"El-Battrawy","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/eurheartj\/ehaa942","article-title":"Brugada syndrome genetics is associated with phenotype severity","volume":"42","author":"Ciconte","year":"2021","journal-title":"Eur Heart J"},{"key":"2021070720500789700_ehab154-B24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/eurheartj\/ehab071","article-title":"Common modulators of Brugada syndrome phenotype do not affect SCN5A prognostic value","volume":"42","author":"Pappone","year":"2021","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/13\/1185\/36846924\/ehab154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/13\/1185\/36846924\/ehab154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:57:14Z","timestamp":1671767834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/13\/1185\/6207272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":24,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,4,1]]},"published-print":{"date-parts":[[2021,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab154","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"type":"print","value":"0195-668X"},{"type":"electronic","value":"1522-9645"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,3,31]]}}}